The size of the In-Vitro fertilization (IVF) market in Europe is expected to reach USD 2.31 billion by 2028 from USD 1.13 billion in 2023, growing at a CAGR of 15.4% during the forecast period. In 2020, the EU5 (Germany, France, United Kingdom, Spain, and Italy) collectively accounted for around three-fifths of the European market share. Moreover, most fertility clinics in Europe offer services to the population to prevent infertility, due to which this region has witnessed a high and increased frequency of fertility clinics.
The declining fertility rate is one of the major factors propelling the European IVF market growth. In recent years, Europe has seen a rapid decline in fertility due to several factors, such as increasing closures of several fertility centers during the pandemic and increasing infertility rates among men and women due to changes in their lifestyles. In addition, increasing obesity and adopting unhealthy lifestyles due to rising working hours is a significant issues among men and women, which causes infertility.
In addition, the growing number of advancements in infertility treatment procedures are promoting the growth rate of the European IVF market. Researchers are focusing on developing various devices and equipment for making the infertility treatment process easy with a smaller number of sessions, less pain, and an increase in the success rate of the treatment. Increasing investment by the government also helps market growth. In addition, pharmaceutical companies are showing interest in manufacturing different types of drugs for treating infertility in people who are at an early age and have more chances to conceive by taking the pills.
The IVF market in European countries such as the UK, Germany, and France is growing consistently. The regulatory scenario in the UK, such as the U.K. Human Fertilization and Embryo Authority (HFEA), is tightly regulating the operation of in vitro fertilization treatments and research in the U.K., favoring the regional market growth. The falling birth rate in Germany is plus to the market’s growth rate. The availability the reimbursement policies in the European region is anticipated to result in the IVF market growth in Europe.
In addition, factors such as rising public and private sector participation in the IVF market, increasing support for the growth of fertility clinics and infertility services across the European region, the growing focus of market participants towards fertility protection activities, and education to improve the network for sharing best practices and brief information on infertility and fertility are anticipated to drive the European IVF market. The number of IVF centers in Europe is growing considerably due to the growing population and rising trend of delayed pregnancy among women. Furthermore, as the age increases, the chances of natural conception decrease, leading to an increase in infertility problems; as a result, more women are forced to use in vitro fertilization banking services to increase the success rate, which is expected to boost the market growth. In addition, because these centers strive to provide public funding for all lines of fertility treatment to eliminate the stigma associated with infertility, the IVF market is anticipated to grow further.
Furthermore, the growing awareness regarding the availability of various treatment options for infertility is supporting the European IVF market growth. Furthermore, the increasing promotional efforts of the market participants to promote awareness of infertile centers and infertility treatment through social media and TV helps spread awareness about the treatment process and the cost, which helps in adopting the treatment among people in rural areas and uneducated people.
However, high costs associated with IVF treatments and strict government regulations are anticipated to hamper the growth rate of the regional market growth. In addition, a patient may need multiple pregnancy cycles due to the lower success rate of IVF procedures, which increases the total cost. The average cost of this procedure is approximately USD 15,125 to USD 25,300, which is often a significant barrier to adopting the technique. Besides, ethical considerations and lack of reimbursement are other challenges hampering the market's growth. In addition, the lack of reimbursements and ethical considerations against IVF further inhibit the European IVF market growth.
This research report on the Europe IVF Market has been segmented and sub-segmented into the following categories:
By Reagents and Media:
By End Users:
The European region enjoys an excellent reputation in the global IVF market, as it was the first to introduce the IVF procedure. Furthermore, among all the other regions of the world, Europe has always been at the forefront of providing assisted reproduction services, mainly due to the help and support from the European Society of Human Reproduction and Embryology. As a result, approximately 37% of the global in vitro fertilization (IVF) market was accounted for by Europe in 2020, which proves that the IVF market in Europe has the highest share among other regions. This is mainly due to various favorable government policies offered to women for infertility treatment, leading to growing support from health insurance players in this region.
However, the UK IVF market is expected to hold considerable of the European market during the forecast period. The added advantage of primarily offering services free of charge by the National Health Service in the country of United Kingdom is further leading to more adoption of fertility clinics, ultimately leading to the growth of the IVF services market. Nearly one in seven couples have difficulty conceiving in this region. Therefore, the United Kingdom government is focused on launching different facility centers for the infertile, training the healthcare provider about the new type of procedures for the patients to increase the success rate.
The IVF market in France accounted for the highest number of IVF cycles per year in 2022. The increasing number of infertility centers in France is one of the key factors promoting the market’s growth rate in France.
The Spanish IVF market is one of the potential regional markets in the European region. It is estimated to grow at a healthy CAGR during the forecast period owing to the growing fertility tourism and the high success rates of the treatments provided.
KEY MARKET PLAYERS:
Companies playing a dominant role in the European IVF Market profiled in this report are Cooper Surgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
The European IVF market is expected to be 980 million in 2022.
The EU5 countries accounted for the largest share of the European IVF market in 2021.
Cooper Surgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.) are some of the noteworthy companies in the European IVF market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org